Project Grant R01CA305504
Award Date 9/1/26
Completion Date 8/31/30
Dollars Obligated $709K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, NY 10065, USA
Similar Awards
- The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $699,794 on August 25, 2026, under the Cancer Treatment Research program (CFDA 93.395) to modulate the tumor microenvironment and enhance nanoparticle delivery to cancer cells. The project addresses limited nanoparticle efficacy in cancer therapies caused by nonspecific uptake in the mononuclear phagocyte system and interception by tumor-resident macrophages, which results in median tumor uptake of under 1...
- The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $1,467,021 on April 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate tumor regenerative cell populations and develop L1CAM-targeted antibody-drug conjugates that may overcome resistance to neoadjuvant therapy in locally advanced rectal cancer. The project will use genomic and transcriptomic analysis of pre-treatment rectal tumors, mechanistic studies in patient-derived organoid...
- The National Cancer Institute awarded the Sloan-Kettering Institute for Cancer Research $671,252 on July 1, 2026, under Cancer Biology Research (CFDA 93.396) to investigate CD4 T cell and dendritic cell interactions that license CD8 T cell cytotoxicity against tumor cells. The research examines how tumor-specific CD4 T cells, CD8 T cells, and dendritic cells form three-cell clusters (triads) within tumors to overcome CD8 T cell dysfunction and exhaustion. Prior work by the recipient demonstrated...
- The National Cancer Institute awarded the Sloan-Kettering Institute for Cancer Research $546,842 on July 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to characterize germline determinants of tumor development and response to treatment through integration of germline, somatic, histological, and clinical data across multiple institutional cohorts. The research investigates how inherited, population-level germline variants influence tumor development and...
- The National Cancer Institute, a component of the Department of Health and Human Services, awarded $644,423 to Sloan-Kettering Institute for Cancer Research on June 18, 2026, under the Cancer Treatment Research program (CFDA 93.395). The recipient will develop short-wave infrared (SWIR) Cerenkov luminescence imaging (SWIR-CLI) to visualize the distribution of therapeutic radiotracers and improve monitoring of targeted radiotherapy. Current Cerenkov luminescence imaging requires light-tight...
- The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $731,937 on August 11, 2026, under the Cancer Biology Research program (CFDA 93.396) to develop and optimize computational immunology tools for predicting T-cell receptor specificity to peptide-major histocompatibility complex ligands. The project focuses on refining EnFoldX, an ensemble-based algorithm that leverages protein structure prediction models such as AlphaFold3 to jointly fold TCR:PMHC complexes and...
- The National Institutes of Health National Cancer Institute awarded the Sloan-Kettering Institute for Cancer Research $146,299 on August 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) for a K99 postdoctoral career development grant supporting research into cancer cell surface remodeling and engineered immunotherapy. The funded research investigates how dynamic cell surface changes during cancer progression shape tumor-immune interactions and fibrosis, with particular focus...
- The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $577,331 on August 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to repurpose HSP90 inhibitors as a condensate-directed therapy for receptor tyrosine kinase fusion-driven cancers. The project targets cancers driven by RTK fusions such as EML4-ALK and CCDC6-RET, which account for 3–5 percent of all cancer diagnoses and approximately 225,000 new lung cancer patients annually worldwide. The...
- The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $745,471 on July 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate hematopoietic stem cell-encoded anti-tumor immunity mechanisms in response to intravesical bacillus Calmette-Guerin (BCG) therapy for non-muscle invasive bladder cancer. The research examines how BCG induces long-term tumor-specific T cell immunity and explores upstream mechanisms by which BCG stimulates...
- The National Cancer Institute awarded the Sloan-Kettering Institute for Cancer Research $752,280 on August 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to decode basal cell multipotency as a precursor and therapeutic target in histological transformation across lung cancer subtypes. The award funds research into the molecular and cellular mechanisms driving adenocarcinoma transformation to small cell lung cancer or squamous cell carcinoma histology as a resistance mechanism...